{"entity":{"type":"insider","cik":"0001373110","url":"/insider/0001373110","json_url":"/insider/0001373110.json","name":"Gergen Mark J","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":21,"n_filings":20,"first":"2007-01-04","last":"2024-12-11","span_basis":"filed_date"},"name_variants":[{"name":"Gergen Mark J","source":"filing","n_filings":20,"first_seen":"2007-01-04","last_seen":"2024-12-11"}],"transactions":[{"id":2681456,"accession":"0000950170-24-135466","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-135466","line_url":"/filing/0000950170-24-135466#line-2","is_derivative":false,"issuer_cik":"0001373110","issuer_name":"Poseida Therapeutics, Inc.","issuer_ticker":"PSTX","issuer_name_source":null,"issuer_url":"/issuer/0001373110","owner_cik":"0001373110","owner_name":"Gergen Mark J","owner_display_name":"Gergen Mark J","owner_url":"/insider/0001373110","role":"Director, Officer (Executive Chairman)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive Chairman","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30000.0,"shares_display":"30,000","price_per_share":9.4622,"price_display":"9.46","price_state":"stated","total_value":283866.0,"total_display":"283,866.00","total_whole":"283,866","shares_owned_after":651291.0,"shares_owned_after_display":"651,291","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-10","filed_date":"2024-12-11","scope":"insider"},{"id":3113314,"accession":"0000950170-24-131665","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-131665","line_url":"/filing/0000950170-24-131665#line-2","is_derivative":false,"issuer_cik":"0001373110","issuer_name":"Poseida Therapeutics, Inc.","issuer_ticker":"PSTX","issuer_name_source":null,"issuer_url":"/issuer/0001373110","owner_cik":"0001373110","owner_name":"Gergen Mark J","owner_display_name":"Gergen Mark J","owner_url":"/insider/0001373110","role":"Director, Officer (Executive Chairman)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive Chairman","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30000.0,"shares_display":"30,000","price_per_share":9.27,"price_display":"9.27","price_state":"stated","total_value":278100.0,"total_display":"278,100.00","total_whole":"278,100","shares_owned_after":651291.0,"shares_owned_after_display":"651,291","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-26","filed_date":"2024-11-27","scope":"insider"},{"id":2950157,"accession":"0001190725-16-000301","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001190725-16-000301","line_url":"/filing/0001190725-16-000301#line-3","is_derivative":false,"issuer_cik":"0001373110","issuer_name":"Mirati Therapeutics, Inc.","issuer_ticker":"MRTX","issuer_name_source":null,"issuer_url":"/issuer/0001373110","owner_cik":"0001373110","owner_name":"Gergen Mark J","owner_display_name":"Gergen Mark J","owner_url":"/insider/0001373110","role":"Officer (Executive VP, COO)","role_mark":"O","role_mark_label":"Officer (Executive VP, COO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, COO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":25.9211,"price_display":"25.92","price_state":"stated","total_value":259211.0,"total_display":"259,211.00","total_whole":"259,211","shares_owned_after":5748.0,"shares_owned_after_display":"5,748","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-01-15","filed_date":"2016-01-19","scope":"insider"},{"id":3311944,"accession":"0001264124-12-000078","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001264124-12-000078","line_url":"/filing/0001264124-12-000078#line-1","is_derivative":false,"issuer_cik":"0000881464","issuer_name":"AMYLIN PHARMACEUTICALS INC","issuer_ticker":"AMLN","issuer_name_source":null,"issuer_url":"/issuer/0000881464","owner_cik":"0001373110","owner_name":"Gergen Mark J","owner_display_name":"Gergen Mark J","owner_url":"/insider/0001373110","role":"Officer (SVP, Corporate Development), Other","role_mark":"O","role_mark_label":"Officer (SVP, Corporate Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Corporate Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1846.0,"shares_display":"1,846","price_per_share":17.11,"price_display":"17.11","price_state":"stated","total_value":31585.06,"total_display":"31,585.06","total_whole":"31,585","shares_owned_after":53814.2,"shares_owned_after_display":"53,814.20","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-03-01","filed_date":"2012-03-02","scope":"insider"},{"id":3443795,"accession":"0001264124-12-000057","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001264124-12-000057","line_url":"/filing/0001264124-12-000057#line-2","is_derivative":false,"issuer_cik":"0000881464","issuer_name":"AMYLIN PHARMACEUTICALS INC","issuer_ticker":"AMLN","issuer_name_source":null,"issuer_url":"/issuer/0000881464","owner_cik":"0001373110","owner_name":"Gergen Mark J","owner_display_name":"Gergen Mark J","owner_url":"/insider/0001373110","role":"Officer (SVP, Corporate Development)","role_mark":"O","role_mark_label":"Officer (SVP, Corporate Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Corporate Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7518.0,"shares_display":"7,518","price_per_share":17.0302,"price_display":"17.03","price_state":"stated","total_value":128033.0436,"total_display":"128,033.04","total_whole":"128,033","shares_owned_after":54826.2,"shares_owned_after_display":"54,826.20","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-02-23","filed_date":"2012-02-24","scope":"insider"},{"id":7118151,"accession":"0001367982-07-000451","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001367982-07-000451","line_url":"/filing/0001367982-07-000451#line-2","is_derivative":false,"issuer_cik":"0000881464","issuer_name":"AMYLIN PHARMACEUTICALS INC","issuer_ticker":"AMLN","issuer_name_source":null,"issuer_url":"/issuer/0000881464","owner_cik":"0001373110","owner_name":"Gergen Mark J","owner_display_name":"Gergen Mark J","owner_url":"/insider/0001373110","role":"Officer (Sr VP, Corporate Development)","role_mark":"O","role_mark_label":"Officer (Sr VP, Corporate Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP, Corporate Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":44.0,"price_display":"44.00","price_state":"stated","total_value":22000.0,"total_display":"22,000.00","total_whole":"22,000","shares_owned_after":2937.0,"shares_owned_after_display":"2,937","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-11-01","filed_date":"2007-11-02","scope":"insider"},{"id":7717077,"accession":"0001367982-07-000414","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001367982-07-000414","line_url":"/filing/0001367982-07-000414#line-2","is_derivative":false,"issuer_cik":"0000881464","issuer_name":"AMYLIN PHARMACEUTICALS INC","issuer_ticker":"AMLN","issuer_name_source":null,"issuer_url":"/issuer/0000881464","owner_cik":"0001373110","owner_name":"Gergen Mark J","owner_display_name":"Gergen Mark J","owner_url":"/insider/0001373110","role":"Officer (Sr VP, Corporate Development)","role_mark":"O","role_mark_label":"Officer (Sr VP, Corporate Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP, Corporate Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":50.0,"price_display":"50.00","price_state":"stated","total_value":25000.0,"total_display":"25,000.00","total_whole":"25,000","shares_owned_after":2937.0,"shares_owned_after_display":"2,937","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-10-03","filed_date":"2007-10-04","scope":"insider"},{"id":7002893,"accession":"0001367982-07-000404","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001367982-07-000404","line_url":"/filing/0001367982-07-000404#line-2","is_derivative":false,"issuer_cik":"0000881464","issuer_name":"AMYLIN PHARMACEUTICALS INC","issuer_ticker":"AMLN","issuer_name_source":null,"issuer_url":"/issuer/0000881464","owner_cik":"0001373110","owner_name":"Gergen Mark J","owner_display_name":"Gergen Mark J","owner_url":"/insider/0001373110","role":"Officer (Sr VP, Corporate Development)","role_mark":"O","role_mark_label":"Officer (Sr VP, Corporate Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP, Corporate Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":49.83,"price_display":"49.83","price_state":"stated","total_value":24915.0,"total_display":"24,915.00","total_whole":"24,915","shares_owned_after":2937.0,"shares_owned_after_display":"2,937","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-10-01","filed_date":"2007-10-02","scope":"insider"},{"id":7151705,"accession":"0001367982-07-000378","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001367982-07-000378","line_url":"/filing/0001367982-07-000378","is_derivative":false,"issuer_cik":"0000881464","issuer_name":"AMYLIN PHARMACEUTICALS INC","issuer_ticker":"AMLN","issuer_name_source":null,"issuer_url":"/issuer/0000881464","owner_cik":"0001373110","owner_name":"Gergen Mark J","owner_display_name":"Gergen Mark J","owner_url":"/insider/0001373110","role":"Officer (Sr VP, Corporate Development)","role_mark":"O","role_mark_label":"Officer (Sr VP, Corporate Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP, Corporate Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":49.5,"price_display":"49.50","price_state":"stated","total_value":49500.0,"total_display":"49,500.00","total_whole":"49,500","shares_owned_after":2937.0,"shares_owned_after_display":"2,937","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-09-04","filed_date":"2007-09-06","scope":"insider","n_lines":2},{"id":7860370,"accession":"0001367982-07-000358","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001367982-07-000358","line_url":"/filing/0001367982-07-000358#line-2","is_derivative":false,"issuer_cik":"0000881464","issuer_name":"AMYLIN PHARMACEUTICALS INC","issuer_ticker":"AMLN","issuer_name_source":null,"issuer_url":"/issuer/0000881464","owner_cik":"0001373110","owner_name":"Gergen Mark J","owner_display_name":"Gergen Mark J","owner_url":"/insider/0001373110","role":"Officer (Sr VP, Corporate Development)","role_mark":"O","role_mark_label":"Officer (Sr VP, Corporate Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP, Corporate Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":50.0,"price_display":"50.00","price_state":"stated","total_value":25000.0,"total_display":"25,000.00","total_whole":"25,000","shares_owned_after":2937.0,"shares_owned_after_display":"2,937","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-08-07","filed_date":"2007-08-08","scope":"insider"},{"id":7234024,"accession":"0001367982-07-000342","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001367982-07-000342","line_url":"/filing/0001367982-07-000342#line-2","is_derivative":false,"issuer_cik":"0000881464","issuer_name":"AMYLIN PHARMACEUTICALS INC","issuer_ticker":"AMLN","issuer_name_source":null,"issuer_url":"/issuer/0000881464","owner_cik":"0001373110","owner_name":"Gergen Mark J","owner_display_name":"Gergen Mark J","owner_url":"/insider/0001373110","role":"Officer (Sr VP, Corporate Development)","role_mark":"O","role_mark_label":"Officer (Sr VP, Corporate Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP, Corporate Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":46.5,"price_display":"46.50","price_state":"stated","total_value":23250.0,"total_display":"23,250.00","total_whole":"23,250","shares_owned_after":2937.0,"shares_owned_after_display":"2,937","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-08-01","filed_date":"2007-08-02","scope":"insider"},{"id":8330621,"accession":"0001367982-07-000332","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001367982-07-000332","line_url":"/filing/0001367982-07-000332#line-2","is_derivative":false,"issuer_cik":"0000881464","issuer_name":"AMYLIN PHARMACEUTICALS INC","issuer_ticker":"AMLN","issuer_name_source":null,"issuer_url":"/issuer/0000881464","owner_cik":"0001373110","owner_name":"Gergen Mark J","owner_display_name":"Gergen Mark J","owner_url":"/insider/0001373110","role":"Officer (Sr VP, Corporate Development)","role_mark":"O","role_mark_label":"Officer (Sr VP, Corporate Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP, Corporate Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":45.0,"price_display":"45.00","price_state":"stated","total_value":22500.0,"total_display":"22,500.00","total_whole":"22,500","shares_owned_after":2937.0,"shares_owned_after_display":"2,937","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-07-24","filed_date":"2007-07-25","scope":"insider"},{"id":7118148,"accession":"0001367982-07-000294","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001367982-07-000294","line_url":"/filing/0001367982-07-000294#line-2","is_derivative":false,"issuer_cik":"0000881464","issuer_name":"AMYLIN PHARMACEUTICALS INC","issuer_ticker":"AMLN","issuer_name_source":null,"issuer_url":"/issuer/0000881464","owner_cik":"0001373110","owner_name":"Gergen Mark J","owner_display_name":"Gergen Mark J","owner_url":"/insider/0001373110","role":"Officer (Sr VP, Corporate Development)","role_mark":"O","role_mark_label":"Officer (Sr VP, Corporate Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP, Corporate Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":41.2,"price_display":"41.20","price_state":"stated","total_value":20600.0,"total_display":"20,600.00","total_whole":"20,600","shares_owned_after":2937.0,"shares_owned_after_display":"2,937","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-07-02","filed_date":"2007-07-03","scope":"insider"},{"id":7151689,"accession":"0001367982-07-000271","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001367982-07-000271","line_url":"/filing/0001367982-07-000271#line-2","is_derivative":false,"issuer_cik":"0000881464","issuer_name":"AMYLIN PHARMACEUTICALS INC","issuer_ticker":"AMLN","issuer_name_source":null,"issuer_url":"/issuer/0000881464","owner_cik":"0001373110","owner_name":"Gergen Mark J","owner_display_name":"Gergen Mark J","owner_url":"/insider/0001373110","role":"Officer (Sr VP, Corporate Development)","role_mark":"O","role_mark_label":"Officer (Sr VP, Corporate Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP, Corporate Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":46.16,"price_display":"46.16","price_state":"stated","total_value":46160.0,"total_display":"46,160.00","total_whole":"46,160","shares_owned_after":2937.0,"shares_owned_after_display":"2,937","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-06-01","filed_date":"2007-06-04","scope":"insider"},{"id":7439173,"accession":"0001367982-07-000229","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001367982-07-000229","line_url":"/filing/0001367982-07-000229#line-2","is_derivative":false,"issuer_cik":"0000881464","issuer_name":"AMYLIN PHARMACEUTICALS INC","issuer_ticker":"AMLN","issuer_name_source":null,"issuer_url":"/issuer/0000881464","owner_cik":"0001373110","owner_name":"Gergen Mark J","owner_display_name":"Gergen Mark J","owner_url":"/insider/0001373110","role":"Officer (Sr VP, Corporate Development)","role_mark":"O","role_mark_label":"Officer (Sr VP, Corporate Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP, Corporate Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":45.0,"price_display":"45.00","price_state":"stated","total_value":22500.0,"total_display":"22,500.00","total_whole":"22,500","shares_owned_after":2937.0,"shares_owned_after_display":"2,937","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-05-21","filed_date":"2007-05-23","scope":"insider"},{"id":7318952,"accession":"0001367982-07-000202","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001367982-07-000202","line_url":"/filing/0001367982-07-000202#line-2","is_derivative":false,"issuer_cik":"0000881464","issuer_name":"AMYLIN PHARMACEUTICALS INC","issuer_ticker":"AMLN","issuer_name_source":null,"issuer_url":"/issuer/0000881464","owner_cik":"0001373110","owner_name":"Gergen Mark J","owner_display_name":"Gergen Mark J","owner_url":"/insider/0001373110","role":"Officer (Sr VP, Corporate Development)","role_mark":"O","role_mark_label":"Officer (Sr VP, Corporate Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP, Corporate Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":41.25,"price_display":"41.25","price_state":"stated","total_value":20625.0,"total_display":"20,625.00","total_whole":"20,625","shares_owned_after":2937.0,"shares_owned_after_display":"2,937","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-05-01","filed_date":"2007-05-02","scope":"insider"},{"id":8257846,"accession":"0001367982-07-000152","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001367982-07-000152","line_url":"/filing/0001367982-07-000152#line-2","is_derivative":false,"issuer_cik":"0000881464","issuer_name":"AMYLIN PHARMACEUTICALS INC","issuer_ticker":"AMLN","issuer_name_source":null,"issuer_url":"/issuer/0000881464","owner_cik":"0001373110","owner_name":"Gergen Mark J","owner_display_name":"Gergen Mark J","owner_url":"/insider/0001373110","role":"Officer (Sr VP, Corporate Development)","role_mark":"O","role_mark_label":"Officer (Sr VP, Corporate Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP, Corporate Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":37.47,"price_display":"37.47","price_state":"stated","total_value":18735.0,"total_display":"18,735.00","total_whole":"18,735","shares_owned_after":2937.0,"shares_owned_after_display":"2,937","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-04-02","filed_date":"2007-04-03","scope":"insider"},{"id":6843772,"accession":"0001367982-07-000106","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001367982-07-000106","line_url":"/filing/0001367982-07-000106#line-3","is_derivative":false,"issuer_cik":"0000881464","issuer_name":"AMYLIN PHARMACEUTICALS INC","issuer_ticker":"AMLN","issuer_name_source":null,"issuer_url":"/issuer/0000881464","owner_cik":"0001373110","owner_name":"Gergen Mark J","owner_display_name":"Gergen Mark J","owner_url":"/insider/0001373110","role":"Officer (Sr VP, Corporate Development)","role_mark":"O","role_mark_label":"Officer (Sr VP, Corporate Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP, Corporate Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":37.75,"price_display":"37.75","price_state":"stated","total_value":18875.0,"total_display":"18,875.00","total_whole":"18,875","shares_owned_after":2937.0,"shares_owned_after_display":"2,937","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-03-01","filed_date":"2007-03-02","scope":"insider"},{"id":8072937,"accession":"0001367982-07-000054","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001367982-07-000054","line_url":"/filing/0001367982-07-000054#line-3","is_derivative":false,"issuer_cik":"0000881464","issuer_name":"AMYLIN PHARMACEUTICALS INC","issuer_ticker":"AMLN","issuer_name_source":null,"issuer_url":"/issuer/0000881464","owner_cik":"0001373110","owner_name":"Gergen Mark J","owner_display_name":"Gergen Mark J","owner_url":"/insider/0001373110","role":"Officer (Sr VP, Corporate Development)","role_mark":"O","role_mark_label":"Officer (Sr VP, Corporate Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP, Corporate Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":38.75,"price_display":"38.75","price_state":"stated","total_value":19375.0,"total_display":"19,375.00","total_whole":"19,375","shares_owned_after":2597.0,"shares_owned_after_display":"2,597","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-02-01","filed_date":"2007-02-02","scope":"insider"},{"id":7577652,"accession":"0001367982-07-000004","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001367982-07-000004","line_url":"/filing/0001367982-07-000004#line-2","is_derivative":false,"issuer_cik":"0000881464","issuer_name":"AMYLIN PHARMACEUTICALS INC","issuer_ticker":"AMLN","issuer_name_source":null,"issuer_url":"/issuer/0000881464","owner_cik":"0001373110","owner_name":"Gergen Mark J","owner_display_name":"Gergen Mark J","owner_url":"/insider/0001373110","role":"Officer (Sr VP, Corporate Development)","role_mark":"O","role_mark_label":"Officer (Sr VP, Corporate Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr VP, Corporate Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":36.29,"price_display":"36.29","price_state":"stated","total_value":18145.0,"total_display":"18,145.00","total_whole":"18,145","shares_owned_after":2181.0,"shares_owned_after_display":"2,181","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-01-03","filed_date":"2007-01-04","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":21,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":21,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":21},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001661460","name":"Poseida Therapeutics, Inc.","url":"/issuer/0001661460","role":"Director, Officer (Executive Chairman)","n_filings":2,"first_seen":"2024-11-27","last_seen":"2024-12-11"},{"type":"issuer","type_label":"ISSUER","cik":"0001576263","name":"Mirati Therapeutics, Inc.","url":"/issuer/0001576263","role":"Officer (Executive VP, COO)","n_filings":1,"first_seen":"2016-01-19","last_seen":"2016-01-19"},{"type":"issuer","type_label":"ISSUER","cik":"0000881464","name":"AMYLIN PHARMACEUTICALS INC","url":"/issuer/0000881464","role":"Officer (SVP, Corporate Development), Other","n_filings":17,"first_seen":"2007-01-04","last_seen":"2012-03-02"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001373110","retrieved_at":"2026-08-26T14:03:39+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}